Patents by Inventor Ian Slaymaker

Ian Slaymaker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12264359
    Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a novel DNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA. Methods for making and using and uses of such systems, methods, and compositions and products from such methods and uses are also disclosed and claimed.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: April 1, 2025
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Feng Zhang, Bernd Zetsche, Jonathan S. Gootenberg, Omar O. Abudayyeh, Ian Slaymaker
  • Publication number: 20250101400
    Abstract: The present disclosure provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides mutated Cas13 proteins and their use in modifying target sequences as well as mutated Cas13 nucleic acid sequences and vectors encoding mutated Cas13 proteins and vector systems or CRISPR-Cas13 systems.
    Type: Application
    Filed: December 2, 2024
    Publication date: March 27, 2025
    Inventors: Feng Zhang, Ian Slaymaker, Soumya Kannan, Jonathan Gootenberg, Omar Abudayyeh
  • Patent number: 12123032
    Abstract: Disclosed and claimed are mutation(s) or modification(s) of the CRISPR enzyme, for example a Cas enzyme such as a Cas9, which obtain an improvement, for instance a reduction, as to off-target effects of a CRISPR-Cas or CRISPR-enzyme or CRISPR-Cas9 system or complex containing or including such a mutated or modified Cas or CRISPR enzyme or Cas9. Methods for making and using and uses of such mutated or modified Cas or CRISPR enzyme or Cas9 and systems or complexes containing the same and products from such methods and uses are also disclosed and claimed.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: October 22, 2024
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Feng Zhang, Linyi Gao, Bernd Zetsche, Ian Slaymaker
  • Patent number: 12091709
    Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a novel DNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA Methods for making and using and uses of such systems, methods, and compositions and products from such methods and uses are also disclosed and claimed.
    Type: Grant
    Filed: August 17, 2023
    Date of Patent: September 17, 2024
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Feng Zhang, Bernd Zetsche, Jonathan S. Gootenberg, Omar O. Abudayyeh, Ian Slaymaker
  • Publication number: 20240228988
    Abstract: Provided herein are improved prime editing methods and compositions that allow for efficient and precise editing of target genes.
    Type: Application
    Filed: January 4, 2024
    Publication date: July 11, 2024
    Inventors: Holly A. Rees, Michael Packer, Luis Barrera, Ian Slaymaker
  • Patent number: 12016908
    Abstract: The present invention features compositions and methods for editing deleterious mutations associated with hemoglobinopathies, such as sickle cell disease (SCD). In particular embodiments, the invention provides methods for correcting mutations in a beta globin polynucleotide using modified adenosine base editors termed “ABE8” having unprecedented levels (e.g., >60-70%) of efficiency.
    Type: Grant
    Filed: July 26, 2022
    Date of Patent: June 25, 2024
    Assignee: Beam Therapeutics Inc.
    Inventors: Ian Slaymaker, Nicole Gaudelli, Yi Yu, Bernd Zetsche, David A. Born, Seung-Joo Lee, Michael Packer
  • Publication number: 20240035006
    Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA or RNA-targeting systems comprising a novel DNA or RNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA.
    Type: Application
    Filed: November 14, 2022
    Publication date: February 1, 2024
    Applicants: The Broad Institute, Inc., Massachusetts Institute of Technology, University of Tokyo, The United States of America, as Represented by the Secretary Dept of Health and Human Services
    Inventors: Takashi Yamano, Hiroshi Nishimasu, Bernd Zetsche, Ian Slaymaker, Yinqing Li, Iana Fedorova, Kira Makarova, Linyi Gao, Eugene Koonin, Feng Zhang, Osamu Nureki
  • Patent number: 11781172
    Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a novel DNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA. Methods for making and using and uses of such systems, methods, and compositions and products from such methods and uses are also disclosed and claimed.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: October 10, 2023
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Feng Zhang, Bernd Zetsche, Jonathan S. Gootenberg, Omar O. Abudayyeh, Ian Slaymaker
  • Patent number: 11773432
    Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a novel DNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA. Methods for making and using and uses of such systems, methods, and compositions and products from such methods and uses are also disclosed and claimed.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: October 3, 2023
    Assignees: THE BROAD INSTITUTE INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Feng Zhang, Bernd Zetsche, Johnathan S. Gootenberg, Omar O. Abudayyeh, Ian Slaymaker
  • Patent number: 11752202
    Abstract: The present invention features compositions and methods for editing deleterious mutations associated with hemoglobinopathies, such as sickle cell disease (SCD). In particular embodiments, the invention provides methods for correcting mutations in a beta globin polynucleotide using modified adenosine base editors termed “ABE8” having unprecedented levels (e.g., >60-70%) of efficiency.
    Type: Grant
    Filed: April 13, 2022
    Date of Patent: September 12, 2023
    Assignee: Beam Therapeutics Inc.
    Inventors: Ian Slaymaker, Nicole Gaudelli, Yi Yu, Bernd Zetsche, David A. Born, Seung-Joo Lee, Michael Packer
  • Patent number: 11634755
    Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a novel DNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA. Methods for making and using and uses of such systems, methods, and compositions and products from such methods and uses are also disclosed and claimed.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: April 25, 2023
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TEOHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Feng Zhang, Bernd Zetsche, Johnathan S. Gootenberg, Omar O. Abudayyeh, Ian Slaymaker
  • Publication number: 20220364071
    Abstract: The present disclosure provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides mutated Cas13 proteins and their use in modifying target sequences as well as mutated Cas13 nucleic acid sequences and vectors encoding mutated Cas13 proteins and vector systems or CRISPR-Cas13 systems.
    Type: Application
    Filed: July 31, 2019
    Publication date: November 17, 2022
    Applicants: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Feng Zhang, Ian Slaymaker, Soumya Kannan, Jonathan Gootenberg, Omar Abudayyeh
  • Patent number: 11459557
    Abstract: Methods and compositions for inducing a plurality of mutations in transgenic Cas9 eukaryotes to model a neuronal disease or disorder. The invention further comprehends testing putative treatments with such models, e.g., testing putative chemical compounds that may be pharmaceutically relevant for treatment or gene therapy that may be relevant for treatment, or combinations thereof. The invention allows for the study of genetic diseases and putative treatments to better understand and alleviate a genetic disease or a condition, e.g., autism, autism-spectrum disease or disorder, obsessive-compulsive disorder, or psychiatric disorders.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: October 4, 2022
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology
    Inventors: Randall Jeffrey Platt, Feng Zhang, Ian Slaymaker
  • Patent number: 11344609
    Abstract: The present invention features compositions and methods for editing deleterious mutations associated with hemoglobinopathies, such as sickle cell disease (SCD). In particular embodiments, the invention provides methods for correcting mutations in a beta globin polynucleotide using modified adenosine base editors termed “ABE8” having unprecedented levels (e.g., >60-70%) of efficiency.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: May 31, 2022
    Assignee: Beam Therapeutics Inc.
    Inventors: Ian Slaymaker, Nicole Gaudelli, Yi Yu, Bernd Zetsche, David A. Born, Seung-Joo Lee, Michael Packer
  • Patent number: 11155803
    Abstract: The disclosure provides compositions comprising novel adenosine base editors (e.g., ABE8) that have increased efficiency and methods of using these adenosine deaminase variants for editing a target sequence.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: October 26, 2021
    Assignee: BEAM THERAPEUTICS INC.
    Inventors: Nicole Gaudelli, Michael Packer, Ian Slaymaker, Yi Yu, Bernd Zetsche, Jason Michael Gehrke, Natalie Petrossian, Angelica Messana, Yvonne Aratyn, Francine Gregoire, Genesis Lung, Shaunna Berkovitch, David A. Born, Seung-Joo Lee
  • Publication number: 20210317479
    Abstract: Disclosed are compositions and methods involving nucleic acid assemblies that enclose and/or protect cargo. Disclosed are compositions that include a nucleic acid assembly comprising one or more nucleic acid molecules and cargo comprising two or more cargo molecules. The nucleic acid assembly can have physiochemical properties that: (i) enhance targeting of the composition to one or more types of cells, tissues, organs, or microenvironments relative to other types of cells, tissues, organs, or microenvironments in vivo; (ii) enhance stability and/or half-life of the composition in vivo; and/or (iii) reduce immunogenicity of the composition. The nucleic acid assembly and/or cargo can have features that enhance intracellular trafficking of nucleic acid assembly and/or its cargo. The cargo can be enclosed and/or protected by the nucleic acid assembly. Some or all of the cargo molecules in the composition can be present in a defined stoichiometric ratio.
    Type: Application
    Filed: September 6, 2019
    Publication date: October 14, 2021
    Inventors: Feng Zhang, Tyson Shepherd, Rémi Veneziano, Mark Bathe, Ian Slaymaker, Bernd Zetsche
  • Patent number: 11142760
    Abstract: The present invention features compositions and methods for editing deleterious mutations associated with hemoglobinopathies, such as sickle cell disease (SCD). In particular embodiments, the invention provides methods for correcting mutations in a beta globin polynucleotide using modified adenosine base editors termed “ABE8” having unprecedented levels (e.g., >60-70%) of efficiency.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: October 12, 2021
    Assignee: Beam Therapeutics Inc.
    Inventors: Ian Slaymaker, Nicole Gaudelli, Yi Yu, Bernd Zetsche, David A. Born, Seung-Joo Lee, Michael Packer
  • Patent number: 11091798
    Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a novel DNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA. Methods for making and using and uses of such systems, methods, and compositions and products from such methods and uses are also disclosed and claimed.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: August 17, 2021
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Feng Zhang, Bernd Zetsche, Jonathan S. Gootenberg, Omar O. Abudayyeh, Ian Slaymaker
  • Publication number: 20210163944
    Abstract: The disclosure provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting Cas12b effector protein and at least one targeting nucleic acid component like a guide RNA or crRNA.
    Type: Application
    Filed: August 7, 2019
    Publication date: June 3, 2021
    Applicants: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Feng Zhang, Jonathan Strecker, Ian Slaymaker, Sara Jones
  • Publication number: 20210130800
    Abstract: The present disclosure provides for systems, methods, and compositions for targeting and editing nucleic acids. In particular, the present disclosure provides non-naturally occurring or engineered RNA-targeting systems comprising a RNA-targeting Cas13 protein, at least one guide molecule, and at least one adenosine deaminase protein or catalytic domain thereof.
    Type: Application
    Filed: October 23, 2018
    Publication date: May 6, 2021
    Applicants: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Feng Zhang, Jonathan Gootenberg, David Benjamin Turitz Cox, Omar Abudayyeh, Ian Slaymaker